RVNC News and Press, Revance Therapeutics Inc. From 02/27/23

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43 rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts. President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participat...

- New data demonstrate duration of efficacy up to 26-weeks and favorable safety profile with up to 5 injection cycles for Cervical Dystonia - Revance Therapeutics, Inc . (RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Associati...

Conference Call Scheduled for Tuesday, February 28, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host ...

Summary Evolus' Jeuveau continues to see growth. Recent release of unaudited full-year 2022 financials showed revenues reaching $148.6 million, which was an increase of 49% over same period in 2021. It predicts that it will reach organic net revenue of $500 million by 2028. Interim ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year. As a result, those who invest in pharma stocks...

Summary According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's biosimilars will go on sale in the United States. Botox Cosmetic sales wer...

Summary The global Botulinum Toxin market should reach $9.09 billion by 2029. Technically, Revance Therapeutics, Inc.'s DAXXIFY is the first time in over 30 years that a truly innovative neurotoxin has been brought to the aesthetics market. The outcome of the product's two quarter p...

Revance Therapeutics ( NASDAQ: RVNC ) expects preliminary unaudited Q4 RHA collection revenue to be between $34M and $35M, a 45% rise Y/Y. ( RVNC ) has risen ~45%. Revance expects preliminary unaudited Daxxify revenue from PrevU, its early experience program, to b...

DAXXIFY ® PrevU program off to strong start with ~400 select practice partners and thousands of patients treated, generating positive feedback and strong, early uptake Preliminary unaudited Q4 DAXXIFY® revenue from PrevU of between $10.5 million and $11.5 million Pre...

- Prescription Drug User Fee Act (PDUFA) date of August 19, 2023 - Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (Daxibotulinumtoxin...